Name: Name:PD-126055 free acid
Brand: AABLOCKS
SKU: AA009CJM
Rating: 90 (10 reviews)

Catalog No.: AA009CJM

1316755-16-4 | PD-126055 free acid

Pack Size： 1mg

Purity： ≥95%

in stock

$80.00 $56.00

Pack Size： 5mg

Purity： ≥95%

in stock

$213.00 $149.00

Pack Size： 10mg

Purity： ≥95%

in stock

$383.00 $268.00

Pack Size： 25mg

Purity： ≥95%

in stock

$765.00 $535.00

Quantity

- +

Add to Card

Order Now

bulk Quotation Request

Technical Information

Catalog Number: AA009CJM

Chemical Name: PD-126055 free acid

CAS Number: 1316755-16-4

Molecular Formula: C32H29NO5

Molecular Weight: 507.5764

MDL Number: MFCD28502251

SMILES: COc1ccc2c(c1OCc1ccccc1)C[C@H](N(C2)C(=O)C(c1ccccc1)c1ccccc1)C(=O)O

Properties

Complexity: 752

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 1

Defined Bond Stereocenter Count: 0

Formal Charge: 0

Heavy Atom Count: 38

Hydrogen Bond Acceptor Count: 5

Hydrogen Bond Donor Count: 1

Isotope Atom Count: 0

Rotatable Bond Count: 8

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 5.6

Downstream Synthesis Route

CASUnavailable

1316755-16-4

[1]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-US2012/22101,2012,A1Locationinpatent:Page/Pagecolumn18

PD126055

3984-14-3

C34H35N3O6S

[1]Patent:WO2015/3223,2015,A1.Locationinpatent:Page/Pagecolumn53

1356460-45-1

1316755-16-4

[1]Wakchaure,PrasadB.;Bremberg,Ulf;Wannberg,Johan;Larhed,Mats[Tetrahedron,2015,vol.71,#38,p.6881-6887]

Literature fold

Title: Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain.

Journal: Journal of the peripheral nervous system : JPNS20141001

Title: EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.

Journal: Lancet (London, England)20140510

Title: Angiotensin II: from blood pressure to pain control.

Journal: Lancet (London, England)20140510

Title: Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.

Journal: Pain medicine (Malden, Mass.)20130501

Title: Intraneuronal angiotensinergic system in rat and human dorsal root ganglia.

Journal: Regulatory peptides20100608

Title: Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system.

Journal: Endocrinology20080701

Title: Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.

Journal: Journal of medicinal chemistry19960202

Title: Suguru Koyama,et al. An Electroencephalography Bioassay for Preclinical Testing of Analgesic Efficacy.

Title: Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38.

Title: Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.Lancet. 2014 May 10;383(9929):1637-47.